A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer

@article{Ho2017ASO,
  title={A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer},
  author={T. Ho and R. N{\'u}{\~n}ez-Nateras and Yue-xian Hou and A. Bryce and D. Northfelt and A. Dueck and B. Wong and M. Stanton and R. Joseph and E. Castle},
  journal={Clinical Genitourinary Cancer},
  year={2017},
  volume={15},
  pages={196–202.e1}
}
Micro‐Abstract A study to evaluate the toxicity of combination bicalutamide and raloxifene was conducted in patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose reductions were required. The patient assessment of quality of life showed no statistically significant changes. The combination of bicalutamide and raloxifene treatment was well tolerated. Background: Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER‐&agr; and ER‐&bgr;, and estrogen‐based… Expand
View on Wolters Kluwer
prostatecancerreports.org
4 Citations
Background Citations
2
Methods Citations
1

4 Citations

Citation Type

Citation Type

Raloxifene: Promises and Challenges as a Drug Treatment for Castrate Resistant Prostate Cancer
  • 2
A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation
  • 1
  • PDF
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
  • 17
  • PDF
Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa
  • 1
  • PDF

References

SHOWING 1-10 OF 55 REFERENCES
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
  • 37
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
  • 91
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
  • 107
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
  • 104
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
  • 43
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
  • 22
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
  • 175
Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.
  • 52
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
  • 13
Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptorα and β
  • 37
...
1
2
3
4
5
...